Dilated Cardiomyopathy

DCM is a phenotype of left-ventricular dilation and systolic dysfunction that is disproportionate to coronary artery disease or abnormal loading conditions; it is not synonymous with idiopathic or nonischemic disease. The first diagnostic task is therefore to determine whether ischemic disease, severe hypertension, valvular disease, congenital disease, acute inflammatory disease, or infiltration better explains the degree of ventricular dysfunction. jacc+1jaccThe Diagnosis and Evaluation of Dilated CardiomyopathyPubMedRisk Stratification in Nonischemic Dilated Cardiomyopathy Using CMR Imaging: A Systematic Review and Meta-Analysis - PMC

Obtain transthoracic echocardiography to document LV and right-ventricular size and function, valve disease, atrial size, and restrictive physiology. Pair natriuretic peptide and troponin testing with the initial laboratory assessment; guideline syntheses consistently identify both as part of the core DCM workup. PubMedPubMedDiagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations

Escalate patients with progressive or refractory heart failure toward an advanced-heart-failure pathway, including consideration of mechanical circulatory support or transplantation when appropriate. DCM remains a leading indication for transplantation, and reported 5-year mortality in nonischemic DCM reaches up to 20% from progressive heart failure or sudden cardiac death. jacc+1jaccThe Diagnosis and Evaluation of Dilated CardiomyopathyPubMedRisk Stratification in Nonischemic Dilated Cardiomyopathy Using CMR Imaging: A Systematic Review and Meta-Analysis - PMC

Obtain thyroid function tests, HIV serology, electrolytes, and iron studies in the baseline evaluation for secondary causes. Add urine toxicology testing and alcohol testing when history or presentation suggests substance exposure. These tests identify potentially reversible contributors before the DCM phenotype is called idiopathic. PubMedPubMedDilated Cardiomyopathy - StatPearls - NCBI Bookshelf

Separate acquired triggers from predisposing substrate rather than treating them as mutually exclusive. Alcohol-associated and cancer therapy-associated cardiomyopathy may have genetic susceptibility, and peripartum cardiomyopathy can occur within familial DCM. A temporal association with alcohol, chemotherapy, or pregnancy should therefore not end the inherited-disease evaluation when family history, arrhythmia, or conduction disease is present. NatureNaturePathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine | Nature Reviews Cardiology

Request genetic counseling and phenotype-directed genetic testing in an affected proband when the phenotype or pedigree suggests inherited disease. Consensus guidance supports testing for diagnosis, prognostic assessment, therapeutic and reproductive decisions, and cascade testing of relatives; testing should prioritize genes with strong association to the observed phenotype. AHA Journals+1AHA JournalsEvidence-Based Assessment of Genes in Dilated CardiomyopathyPubMedDiagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations

Interpret a genetic result in the clinical context. In advanced or “burned-out” hypertrophic cardiomyopathy, LVEF of 50% or less with modest residual hypertrophy can mimic DCM; detailed pedigree review, CMR, and genetic testing may establish the diagnosis when imaging is nondiagnostic. jaccjacc“Burned-Out” Hypertrophic Cardiomyopathy: Overlap on Cardiac MRI With Other Nonischemic Cardiomyopathies

Perform comprehensive CMR during the initial evaluation of suspected nonischemic cardiomyopathy when feasible. Cine imaging quantifies ventricular function and volumes, while T1 mapping, T2 mapping, and LGE add tissue characterization that can identify infarction, edema, diffuse fibrosis, focal replacement fibrosis, and infiltrative patterns. CMR findings must be integrated with phenotype, ECG, exposure history, and pedigree. jaccjaccRole of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy

Interpret LGE distribution rather than merely its presence. Septal midwall stripe-like or patchy LGE is characteristic of nonischemic DCM and was present in 34% of DCM compared with 10% of ischemic cardiomyopathy in one multicenter cohort; it was associated with larger LV volumes, lower LVEF, and adverse events. ScienceDirectScienceDirectSeptal Midwall Late Gadolinium Enhancement in Ischemic Cardiomyopathy and Nonischemic Dilated Cardiomyopathy—Characteristics and Prognosis - ScienceDirect Conversely, subendocardial or transmural LGE redirects the differential toward prior infarction. jaccjaccThe Diagnosis and Evaluation of Dilated Cardiomyopathy

Use LGE as an additive risk marker, not as a stand-alone ICD indication. Ischemic-pattern LGE was observed in 7% of patients labeled DCM without significant coronary artery disease or infarction history and was associated with a 36% versus 23% 5-year risk of death, major ventricular arrhythmia, transplantation, or ventricular assist device compared with nonischemic LGE. ScienceDirectScienceDirectPrevalence and prognostic significance of ischemic late gadolinium enhancement pattern in non-ischemic dilated cardiomyopathy - ScienceDirect

Repeat CMR with LGE when a patient with DCM or genetic cardiomyopathy clinically deteriorates, because interval tissue characterization may clarify progression or a change in substrate. jaccjaccRole of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy CMR parameters may also help estimate reverse-remodeling potential, but definitions of reverse remodeling and predictive performance vary across studies; do not defer an otherwise indicated device solely on an imaging prediction. ScienceDirectScienceDirectCardiac magnetic resonance imaging to predict left ventricular reverse remodelling in non-ischaemic dilated cardiomyopathy: a systematic review and meta-analysis - ScienceDirect

Manage systolic DCM with foundational therapies for HFrEF. Beta-blockers, renin-angiotensin-aldosterone system inhibitors or angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and SGLT2 inhibitors improve survival in HFrEF; these therapies also reduce sudden cardiac death risk. Nature+2NatureComparative analysis of implantable cardioverter-defibrillator efficacy in ischemic and non-ischemic cardiomyopathy in patients with heart failure | Scientific ReportsNatureDilated cardiomyopathy | Nature Reviews Disease PrimersNaturePathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine | Nature Reviews Cardiology In practice, poor achievement of target doses is common, making structured titration and surveillance for blood pressure, renal function, and electrolytes central to follow-up. NatureNatureComparative analysis of implantable cardioverter-defibrillator efficacy in ischemic and non-ischemic cardiomyopathy in patients with heart failure | Scientific Reports

Do not wait for etiologic certainty before starting HFrEF-directed treatment, but pair treatment with elimination of reversible triggers. Remove cardiotoxic exposures when implicated, maintain alcohol abstinence when alcohol toxicity is suspected, and manage pregnancy-associated disease with pregnancy-specific medication constraints and cardio-obstetric coordination. ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists require pregnancy-specific consideration; the pregnancy management literature provides distinct antepartum and postpartum treatment algorithms. BMJ+2BMJCardiomyopathy and pregnancy | HeartNaturePathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine | Nature Reviews CardiologyAHA JournalsDilated Cardiomyopathy | Circulation Research

For primary prevention, evaluate ICD candidacy in symptomatic nonischemic DCM with NYHA class II or III symptoms and LVEF 35% or less after at least 3 months of optimized medical therapy. ScienceDirect+1ScienceDirectCardiac magnetic resonance imaging to predict left ventricular reverse remodelling in non-ischaemic dilated cardiomyopathy: a systematic review and meta-analysis - ScienceDirectPubMedCurrent Management and Treatment - Dilated Cardiomyopathy - NCBI The net benefit is less certain in nonischemic than ischemic cardiomyopathy and should be individualized with age, competing heart-failure mortality, LGE, genotype, arrhythmias, conduction disease, and expected recovery. Nature+2NatureComparative analysis of implantable cardioverter-defibrillator efficacy in ischemic and non-ischemic cardiomyopathy in patients with heart failure | Scientific ReportsPubMedDiagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendationsPubMedCurrent Management and Treatment - Dilated Cardiomyopathy - NCBI

Consider cardiac resynchronization therapy when conventional electrical and heart-failure criteria are met; nonischemic etiology, left bundle branch block, QRS duration of at least 150 ms, female sex, prior heart-failure hospitalization, lower baseline LV end-diastolic volume index, and lower left-atrial volume index have been associated with more favorable reverse remodeling after CRT. PubMedPubMedCurrent Management and Treatment - Dilated Cardiomyopathy - NCBI Continue reassessment because reverse remodeling often begins after 6 months and may continue beyond that interval. ScienceDirectScienceDirectCardiac magnetic resonance imaging to predict left ventricular reverse remodelling in non-ischaemic dilated cardiomyopathy: a systematic review and meta-analysis - ScienceDirect

Treat the proband's etiologic assessment as a family-risk assessment. Familial transmission is identified by clinical and echocardiographic screening in approximately 20% to 35% of DCM cases, supporting systematic pedigree acquisition and family-directed evaluation rather than assuming sporadic disease. PubMedPubMedStem cell therapy for non-ischemic dilated cardiomyopathy: a systematic review and meta-analysis - PMC

When testing identifies a clinically meaningful genetic cause, use genetic counseling to organize cascade testing and phenotype surveillance in relatives. Guideline syntheses support genetic testing because it can clarify diagnosis, prognosis, therapy, reproductive decisions, and management of family members; postmortem testing may also be useful when it changes care for surviving relatives. PubMedPubMedDiagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations

Revisit the working diagnosis when longitudinal data conflict with the initial label. New conduction disease, ventricular arrhythmia, progressive scar on CMR, a newly recognized family history, or a pathogenic genetic result can move a patient from nonspecific DCM to a more specific genetic, inflammatory, infiltrative, or end-stage HCM diagnosis and may change device and family-management decisions. jacc+3jacc“Burned-Out” Hypertrophic Cardiomyopathy: Overlap on Cardiac MRI With Other Nonischemic CardiomyopathiesjaccRole of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic CardiomyopathyNaturePathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine | Nature Reviews CardiologyPubMedDiagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations